Validation of the Nox-T3 Portable Monitor for Diagnosis of Obstructive Sleep Apnea in Patients With Chronic Obstructive Pulmonary Disease

• Published in: Journal of Clinical Sleep Medicine
• Main Authors: Chang, Yuan, Xu, Liyue, Han, Fang, Keenan, Brendan T., Kneeland-Szanto, Elizabeth, Zhang, Rongbao, Zhang, Wei, Yu, Yongbo, Zuo, Yuhua, Pack, Allan I., Kuna, Samuel T.
• Format: Text
• Language: English
• Published: American Academy of Sleep Medicine 2019
• Subjects: Scientific Investigations; Kuna; Rho; Iceland
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457504/; http://www.ncbi.nlm.nih.gov/pubmed/30952218; https://doi.org/10.5664/jcsm.7720

STUDY OBJECTIVES: Clinical practice guidelines recommend polysomnography (PSG) for diagnosis of obstructive sleep apnea (OSA) in patients with major comorbidities. We evaluated home sleep apnea testing (HSAT) using a type 3 portable monitor (PM, Nox-T3, Nox Medical, Reykjavik, Iceland) to diagnose OSA in adults with chronic obstructive pulmonary disease (COPD). METHODS: Ninety adults with COPD (89.0% males, mean ± standard deviation age 66.5 ± 7.8 years, body mass index 27.5 ± 5.8 kg/m(2), forced expiratory volume in the first second/forced vital capacity [FEV(1)/ FVC] 53.5 ± 12.4%, FEV(1) 54.0 ± 18.4% predicted) underwent unattended HSAT followed by an in-laboratory PSG with simultaneous PM recording. RESULTS: Scoring hypopneas with a ≥ 4% oxygen desaturation, the apnea-hypopnea index (AHI) was 16.7 ± 20.6 events/h on HSAT, 20.0 ± 23.3 events/h on in-laboratory PM, and 21.2 ± 26.2 events/h on PSG (P < .0001). Bland-Altman analysis of AHI on HSAT versus PSG showed a mean difference (95% confidence interval) of −5.08 (−7.73, −2.42) events/h (P = .0003) and limits of agreement (± 2 standard deviations) of −30.00 to 19.85 events/h; HSAT underestimated AHI to a greater extent for more severe values (rho = −.529, P < .0001). Using an AHI ≥ 5 events/h to diagnose OSA, HSAT had 95% sensitivity, 78% specificity, 88% positive predictive value, and 89% negative predictive value compared to PSG. Mean oxygen saturation was 93.2 ± 3.7% on PSG, 91.0 ± 3.3% on in-laboratory PM, and 90.8 ± 4.0% on HSAT (P < .0001). Percentage time oxygen saturation ≤ 88% was 17.9 ± 26.4% on HSAT, 17.4 ± 25.5% on in-laboratory PM, and 10.0 ± 21.1% on PSG (P < .0001). CONCLUSIONS: The Nox-T3 PM can be used to diagnose OSA in patients with COPD but, most likely due to differences among pulse oximeters, a greater number of patients with COPD and without OSA qualified for nocturnal oxygen treatment using this PM than PSG. CITATION: Chang Y, Xu L, Han F, Keenan BT, Kneeland-Szanto E, Zhang R, Zhang W, Yu Y, Zuo Y, Pack AI, Kuna ST. ...